Special Issue

Treatment and Molecular Mechanisms of Depression

Message from the Guest Editors

Research has been advancing in the understanding of the molecular mechanisms involved in major depressive disorder (MDD), which may be targets for more effective pharmacological strategies. In addition to the neurotransmission mechanisms that have been evidenced for some time, biological mechanisms, such as epigenetics, inflammation, and neuroinflammation, intracellular signaling, genetic polymorphisms, hypothalamic-pituitary-adrenal (HPA) axis function, among others, have been gaining scientific attention as biological targets for possible new drugs or other therapeutic strategies. This special issue aims to provide articles addressing molecular biological aspects underlying MDD and new drugs or treatment strategies that may target the molecular mechanisms, constituting more effective approaches for treating MDD and treatment-resistant depression (TRD).

Guest Editors

Dr. Zuleide Maria Ignácio

Laboratory of Physiology, Pharmacology and Psychopathology, Graduate Program in Biomedical Sciences, Federal University of Fronteira Sul, Chapecó, SC, Brazil

Dr. Ricieri Mocelin

Laboratory of Translational Neuropsychobiology, Federal University of Fronteira Sul, Passo Fundo, RS, Brazil

Deadline for manuscript submissions

25 February 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/230055

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

